Citations

Clear

58 citation(s) found for "Spitzer, R".

Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Venneti, Sriram , Kawakibi, Abed Rahman , Ji, Sunjong , Waszak, Sebastian M. , Sweha, Stefan R. , Mota, Mateus , Pun, Matthew , Deogharkar, Akash , Chung, Chan , Tarapore, Rohinton S. , Ramage, Samuel , Chi, Andrew , Wen, Patrick Y. , Arrillaga‐Romany, Isabel , Batchelor, Tracy T. , Butowski, Nicholas , Shonka, Nicole , Hall, Matthew D. , Daghistani, Doured , Beccaria, Kévin , Umemura, Yoshie , Garton, Hugh , Franson, Andrea , Schwartz, Jonathan , Kachman, Maureen , Baum, Heidi , Burant, Charles , Mottl, Sophie L. , Cartaxo, Rodrigo T. , John, Vishal , Messinger, Dana , Peterson, Erik , Ravi, Karthik , Waugh, Alyssa , Walling, Dustin , Ding, Yujie , Xia, Ziyun , Hawes, Debra , Yang, Fusheng , Judkins, Alexander R. , Wahl, Daniel , Lyssiotis, Costas A. , Nava, Daniel de la , Eze, Augustine , Spitzer, Jasper , Schmidt, Susanne V. , Cain, Jason E. , Jiang, Li , Agar, Nathalie Y.R. , Zhao, Lili , Mody, Rajen , Kurokawa, Ryo , Yadav, Viveka Nand , Grill, Jacques , Kline, Cassie , Mueller, Sabine , Nazarian, Javad , Allen, Joshua E. , Odia, Yazmín , Butowski, Nicholas A , Sumrall, Ashley , Shonka, Nicole , Harrison, Rebecca A , de Groot, John , Mehta, Minesh P , Hall, Matthew D , Daghistani, Doured , Cloughesy, Timothy F , Ellingson, Benjamin M , Beccaria, Kevin , Varlet, Pascale , Kim, Michelle M , Umemura, Yoshie , Garton, Hugh , Franson, Andrea , Schwartz, Jonathan , Jain, Rajan , Kachman, Maureen , Baum, Heidi , Burant, Charles F , Mottl, Sophie L , Cartaxo, Rodrigo T , John, Vishal , Messinger, Dana , Qin, Tingting , Peterson, Erik , Sajjakulnukit, Peter , Ravi, Karthik , Waugh, Alyssa , Walling, Dustin , Ding, Yujie , Xia, Ziyun , Schwendeman, Anna , Hawes, Debra , Yang, Fusheng , Judkins, Alexander R , Wahl, Daniel , Lyssiotis, Costas A , de la Nava, Daniel , Alonso, Marta M , Eze, Augustine , Spitzer, Jasper , Schmidt, Susanne V , Duchatel, Ryan J , Dun, Matthew D , Cain, Jason E , Jiang, Li , Stopka, Sylwia A , Baquer, Gerard , Regan, Michael S , Filbin, Mariella G , Agar, Nathalie Y R , Zhao, Lili , Kumar-Sinha, Chandan , Mody, Rajen , Chinnaiyan, Arul , Kurokawa, Ryo , Pratt, Drew , Yadav, Viveka N , Grill, Jacques , Kline, Cassie , Mueller, Sabine , Resnick, Adam , Nazarian, Javad , Allen, Joshua E , Odia, Yazmin , Gardner, Sharon L , Koschmann, Carl , Tarapore, Rohinton S , Ji, Sunjong , Wen, Patrick Yung , Arrillaga‐Romany, Isabel , Sumrall, Ashley , Groot, John de , Mehta, Minesh P. , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Kim, Michelle M. , Jain, Rajan , Stopka, Sylwia A. , Baquer, Gerard , Regan, Michael S. , Koschmann, Carl

Mayo Clinic

Cancer Discovery | August 16, 2023 | Volume: 13 | Issue: 11 | Pages: 2370-2393

10.1158/2159-8290.cd-23-0131 | PMID 37584601 Get It

Abstract Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this finding remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/cerebrospinal fluid (CSF) correlate samples from patients treated in two completed multisite clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, whereas those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle–related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuroglial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction. Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in H3K27M-mutant DMG beyond radiation. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways and reverses pathognomonic H3K27me3 reduction. This article is featured in Selected Articles from This Issue, p. 2293
At-Home Use of a Pregnancy-Specific Zone-MPC Closed-Loop System for Pregnancies Complicated by Type 1 Diabetes: A Single-Arm, Observational Multicenter Study
Levy, Carol J. , Kudva, Yogish C. , Özaslan, Başak , Castorino, Kristin , O’Malley, Grenye , Kaur, Ravinder Jeet , Levister, Camilla, Church, Mei Mei , Desjardins, Donna, McCrady-Spitzer, Shelly , Ogyaadu, Selassie, Trinidad, Mari Charisse, Reid, Corey, Rizvi, Shafaq, Kremers, Walter K. , Pinsker, Jordan E. , Dassau, Eyal , Zaniletti, Isabella, Dassau, Eyal , Levy, Carol J , Kremers, Walter K , Deshpande, Sunil , Zaniletti, Isabella , Doyle, Francis J.

Mayo Clinic

Diabetes Care | May 17, 2023 | Volume: 46 | Issue: 7 | Pages: 1425-1431

10.2337/dc23-0173 | PMID 37196353 Get It

OBJECTIVE There are no commercially available hybrid closed-loop insulin delivery systems customized to achieve pregnancy-specific glucose targets in the U.S. This study aimed to evaluate the feasibility and performance of at-home use of a zone model predictive controller–based closed-loop insulin delivery system customized for pregnancies complicated by type 1 diabetes (CLC-P). RESEARCH DESIGN AND METHODS Pregnant women with type 1 diabetes using insulin pumps were enrolled in the second or early third trimester. After study sensor wear collecting run-in data on personal pump therapy and 2 days of supervised training, participants used CLC-P targeting 80–110 mg/dL during the day and 80–100 mg/dL overnight running on an unlocked smartphone at home. Meals and activities were unrestricted throughout the trial. The primary outcome was the continuous glucose monitoring percentage of time in the target range 63–140 mg/dL versus run-in. RESULTS Ten participants (HbA1c 5.8 ± 0.6%) used the system from mean gestational age of 23.7 ± 3.5 weeks. Mean percentage time in range increased 14.1 percentage points, equivalent to 3.4 h per day, compared with run-in (run-in 64.5 ± 16.3% versus CLC-P 78.6 ± 9.2%; P = 0.002). During CLC-P use, there was significant decrease in both time over 140 mg/dL (P = 0.033) and the hypoglycemic ranges of less than 63 mg/dL and 54 mg/dL (P = 0.037 for both). Nine participants exceeded consensus goals of above 70% time in range during CLC-P use. CONCLUSIONS The results show that the extended use of CLC-P at home until delivery is feasible. Larger, randomized studies are needed to further evaluate system efficacy and pregnancy outcomes.
Association of Polygenic Score and the involvement of Cholinergic and Glutamatergic Pathways with Lithium Treatment Response in Patients with Bipolar Disorder
Amare, Azmeraw T. , Thalamuthu, Anbupalam , Schubert, Klaus Oliver , Fullerton, Janice M. , Heilbronner, Urs , Hsu, Yi‐Hsiang , Shekhtman, Tatyana , Adli, Mazda , Akula, Nirmala , Akiyama, Kazufumi , Ardau, Raffaella , Aubry, Jean‐Michel , Bhattacharjee, Abesh Kumar, Benabarre, Antoni, Bengesser, Susanne , Birner, Armin , Cervantes, Pablo , Chillotti, Caterina , Cichon, Sven , Cruceanu, Cristiana , Dalkner, Nina , Zompo, Maria Del , Forstner, Andreas J. , Frisén, Louise , Frye, Mark A. , Gard, Sébastien, Fallgatter, Andreas J. , Stegmaier, Sophia, Biere, Silvia, Petrova, Kristiyana, Schuster, Ceylan, Heilbronner, Maria , Kálmán, János , Kohshour, Mojtaba Oraki , Schaupp, Sabrina K. , Senner, Fanny , Vogl, Thomas , Anghelescu, Ion‐George , Arolt, Volker , Dietrich, Detlef E. , Figge, Christian, Jäger, Markus , Juckel, Georg , Reimer, Jens , Schmauß, Max, Konrad, Carsten , Hagen, Martin von, Zimmermann, Jörg, Andlauer, Till F. M. , Bermpohl, Felix , Kraft, Vivien , Gryaznova, Anna, Yildiz, Cüneyt , Kircher, Tilo , Gade, Katrin , Trost, Sarah , Lambert, Martin , Rohenkohl, Anja , Grof, Paul , Kahn, Jean‐Pierre, Kassem, Layla, Kittel‐Schneider, Sarah , Ferensztajn‐Rochowiak, Ewa , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leckband, Susan G. , McCarthy, Michael J. , Mitjans, Marina , Mondimore, Francis M. , Nöthen, Markus M. , O’Donovan, Claire , Pisanu, Claudia , Potash, James B. , Schalling, Martin , Schweizer, Barbara , Severino, Giovanni , Shilling, Paul D. , Shimoda, Kazutaka , Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Maj, Mario , Vieta, Eduard , Veeh, Julia, Witt, Stephanie H. , Zandi, Peter P. , Bauer, Michael , Clark, Scott R. , Amare, Azmeraw , Fullerton, Janice M , Papiol, Sergi , Heilbronner, Urs , Biernacka, Joanna , Marie-Claire, Cynthia , Chen, Hsi-Chung , Cichon, Sven , Cruceanu, Cristiana , Czerski, Piotr , Del Zompo, Maria , Etain, B , Jamain, Stéphane , Forstner, Andreas J , Frye, Mark , Garnham, Julie , Goes, Fernando , Grigoroiu-Serbanescu, Maria , Kalman, Janos , Schulte, Eva , Wiltfang, Jens , Andlauer, Till , Kraft, Vivien , Hauser, Joanna , Kuo, Po-Hsiu , Kittel-Schneider, Sarah , Kusumi, Ichiro , Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Tortorella, Alfonso , McCarthy, Michael , Nöthen, Markus M , Novak, Tomas , Pisanu, Claudia , Reif, Andreas , Reininghaus, Eva , Rouleau, Guy Armand , Schalling, Martin , Schofield, Peter R , Severino, Giovanni , Shimoda, Kazutaka , Squassina, Alessio , Stopkova, Pavla , Turecki, Gustavo , Vieta, E , Witt, Stephanie H , Zandi, Peter P , Alda, Martin , Rietschel, Marcella , McMahon, Francis , Millischer, Vincent , Clark, Scott , Thalamuthu, Anbupalam , Kircher, Tilo T J , Schubert, Klaus Oliver , Mitjans, Marina , Ahmed, Muktar Beshir , Hartmann, Simon , Papiol, Sergi , Degenhardt, Franziska , Tekola‐Ayele, Fasil , Hou, Liping , Arias, Bárbara , Backlund, Lena , Bellivier, Frank , Benabarre, Antoni , Biernacka, Joanna M. , Chen, Hsi‐Chung , Czerski, Piotr M. , Dalkner, Nina , DePaulo, J Raymond , Étain, Bruno , Jamain, Stéphane , Falkai, Peter , Grigoroiu‐Serbânescu, Maria , Ethofer, Thomas , Adorjan, Kristina , Budde, Monika , Reich‐Erkelenz, Daniela , Schulte, Eva C. , Dannlowski, Udo , Lang, Fabian U. , Spitzer, Carsten , Schmitt, Andrea , Wiltfang, Jens , Zimmermann, Jörg , Fischer, André , Matura, Silke , Gryaznova, Anna, Falkenberg, Irina , Schmidt, Julia Katharina , Koch, Marius, Haussleiter, Ida Sibylle , Hashimoto, Ryota , Herms, Stefan , Hoffmann, Per , Jiménez, Esther , Kuo, Po‐Hsiu , Kato, Tadafumi , Kelsoe, John R , König, Barbara , Leboyer, Marion , Tortorella, Alfonso , Manchia, Mirko , Martinsson, Lina , McElroy, Susan L. , Colom, Francesc , Monteleone, Palmiero , Nievergelt, Caroline M , Novák, Tomáš , Ozaki, Norio , Pfennig, Andrea , Reif, Andreas , Rybakowski, Janusz K , Schofield, Peter R. , Squassina, Alessio , Stopková, Pavla , Turecki, Gustavo , Wright, Adam, Mitchell, Philip B , Alda, Martin , McMahon, Francis J. , Schulze, Thomas , Baune, Bernhard

Mayo Clinic

No container title available | February 14, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2580252/v1 | PMID 36824922 Get It

Abstract Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consistently effective, with only 30% of patients showing a favorable response to treatment. To provide personalized treatment options for bipolar patients, it is essential to identify prediction biomarkers such as polygenic scores. In this study, we developed a polygenic score for lithium treatment response (Li+PGS) in patients with BD. To gain further insights into lithium's possible molecular mechanism of action, we performed a genome-wide gene-based analysis. Using polygenic score modeling, via methods incorporating Bayesian regression and continuous shrinkage priors, Li+PGS was developed in the International Consortium of Lithium Genetics cohort (ConLi+Gen: N=2,367) and replicated in the combined PsyCourse (N=89) and BipoLife (N=102) studies. The associations of Li+PGS and lithium treatment response — defined in a continuous ALDA scale and a categorical outcome (good response vs. poor response) were tested using regression models, each adjusted for the covariates: age, sex, and the first four genetic principal components. Statistical significance was determined at P<����������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial
Grunberger, George , Weinstock, Ruth S. , Hirsch, Irl B. , DiMeglio, Linda A. , Philis‐Tsimikas, Athena , Kipnes, Mark, Liljenquist, David R., Brazg, Ronald, Kudva, Yogish C. , Buckingham, Bruce A. , Carlson, Anders L. , Criego, Amy , Christiansen, Mark P., Kaiserman, Kevin B. , Forlenza, Gregory P. , Bode, Bruce W. , Slover, Robert H., Keiter, Ashleigh , Ling, Chenxiao , Marinos, Briggitte, Cordero, Toni L. , Shin, John , Lee, Scott W., Rhinehart, Andrew S., Group, for the Adult and Pediatric MiniMed™ HCL Outcomes 6-month RCT: HCL versus CSII Control Study, Downs, Ashleigh, Lange, Samantha , Jost, Emily , KARAMI, ANGELA J., Hamill, Donna, Simha, Vinaya , Desjardins, Donna, Spitzer, Shelly McCrady, Reid, Corey, Kaur, Ravinderjeet, Malone, Halvorson, Mary, Ekhlaspour, Laya , Weir, Christine, Casaubon, Luis, Ang, Lynn , Plunkett, Cindy, Recklein, Carol, Clifton, Mary Jane, Weinstock, Ruth S , Hirsch, Irl B , Kudva, Yogish C. , McGill, Janet B. , Forlenza, Gregory P , Cordero, Toni L , Vigersky, Robert A , Philis-Tsimikas, Athena , Buckingham, Bruce , DiMeglio, Linda , Garg, Satish K. , Lawson, Margaret L. , Pop‐Busui, Rodica , Griffin, Kurt , Vigersky, Robert A. , Group, for the Adult and Pediatric MiniMed™ HCL Outcomes 6-month RCT: HCL versus CSII Control Study, Kaur, Ravinder Jeet , Malone, Stout, Kara Mizokami , Plunkett, Cindy, Williams, Brittany

Mayo Clinic

Diabetes Technology & Therapeutics | December 6, 2022 | Volume: 25 | Issue: 1 | Pages: 1-12

10.1089/dia.2022.0421 | PMID 36472543 Get It

Outpatient Randomized Crossover Comparison of Zone Model Predictive Control Automated Insulin Delivery with Weekly Data Driven Adaptation Versus Sensor-Augmented Pump: Results from the International Diabetes Closed-Loop Trial 4
Pinsker, Jordan E. , Dassau, Eyal , Deshpande, Sunil , Raghinaru, Dan, Buckingham, Bruce A. , Kudva, Yogish C. , Laffel, Lori M. , Church, Mei Mei , Desrochers, Hannah, Ekhlaspour, Laya , Kaur, Ravinder Jeet , Levister, Camilla, Lum, John W. , Kollman, Craig, Ambler-Osborn, Louise, Freiner, Emily , O’Malley, Grenye , Brooks, Danielle , Ogyaadu, Selassie, Plesser, Mitchell, Simha, Vinaya , Desjardins, Donna, McCrady-Spitzer, Shelly , Nolander, Lisa, Hsu, Liana, Passman, Samantha, Campos, Tiffany, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Eggerman, Thomas L., Green, Neal, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Ekhlaspour, Laya , Lum, John , Doyle, Francis J , Buckingham, Bruce , Levy, Carol J. , Shi, Dawei , Kollman, Craig , Doyle, Francis J. , Isganaitis, Elvira , Beck, Roy W. , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | May 12, 2022 | Volume: 24 | Issue: 9 | Pages: 635-642

10.1089/dia.2022.0084 | PMID 35549708 Get It

Background: Automated insulin delivery (AID) systems have proven effective in increasing time-in-range during both clinical trials and real-world use. Further improvements in outcomes for single-hormone (insulin only) AID may be limited by suboptimal insulin delivery settings. Methods: Adults (≥18 years of age) with type 1 diabetes were randomized to either sensor-augmented pump (SAP) (inclusive of predictive low-glucose suspend) or adaptive zone model predictive control AID for 13 weeks, then crossed over to the other arm. Each week, the AID insulin delivery settings were sequentially and automatically updated by an adaptation system running on the study phone. Primary outcome was sensor glucose time-in-range 70–180 mg/dL, with noninferiority in percent time below 54 mg/dL as a hierarchical outcome. Results: Thirty-five participants completed the trial (mean age 39 ± 16 years, HbA1c at enrollment 6.9% ± 1.0%). Mean time-in-range 70–180 mg/dL was 66% with SAP versus 69% with AID (mean adjusted difference +2% [95% confidence interval: −1% to +6%], P = 0.22). Median time <70 mg/dL improved from 3.0% with SAP to 1.6% with AID (−1.5% [−2.4% to −0.5%], P = 0.002). The adaptation system decreased initial basal rates by a median of 4% (−8%, 16%) and increased initial carbohydrate ratios by a median of 45% (32%, 59%) after 13 weeks. Conclusions: Automated adaptation of insulin delivery settings with AID use did not significantly improve time-in-range in this very well-controlled population. Additional study and further refinement of the adaptation system are needed, especially in populations with differing degrees of baseline glycemic control, who may show larger benefits from adaptation.
Hypoglycemia in Prospective Multicenter Study of Pregnancies with Pre-Existing Type 1 Diabetes on Sensor-Augmented Pump Therapy: The LOIS-P Study
Kaur, Ravinder Jeet , Özaslan, Başak , Pinsker, Jordan E. , Trinidad, Mari Charisse, O’Malley, Grenye , Desjardins, Donna, Castorino, Kristin , Levister, Camilla, Reid, Corey, McCrady-Spitzer, Shelly , Ogyaadu, Selassie, Church, Mei Mei , Piper, Molly, Kremers, Walter K. , Rosenn, Barak, Dassau, Eyal , Kudva, Yogish C. , Doyle, Francis J , Dassau, Eyal , Kudva, Yogish C. , Kremers, Walter K , Smith, Byron H. , Doyle, Francis J. , Levy, Carol J.

Mayo Clinic

Diabetes Technology & Therapeutics | March 29, 2022 | Volume: 24 | Issue: 8 | Pages: 544-555

10.1089/dia.2021.0479 | PMID 35349353 Get It

Background: Pregnancies in type 1 diabetes are high risk, and data in the United States are limited regarding continuous glucose monitoring (CGM)-based hypoglycemia throughout pregnancy while on sensor-augmented insulin pump therapy. Materials and Methods: Pregnant women with type 1 diabetes in the LOIS-P Study (Longitudinal Observation of Insulin use and glucose Sensor metrics in Pregnant women with type 1 diabetes using continuous glucose monitors and insulin pumps) were enrolled before 17 weeks gestation at three U.S. centers and we used their personal insulin pump and a study Dexcom G6 CGM. We analyzed data of 25 pregnant women for CGM hypoglycemia based on international consensus guidelines for percentage time <63 and 54 mg/dL, hypoglycemic events and prolonged hypoglycemia events for 24-h, daytime, and overnight periods, and severe hypoglycemia (SH) episodes. Results: For a 24-h period, biweekly median percentage of time <63 mg/dL ranged from 0.8% at biweek 4–5 to 3.7% at biweek 14–15 with high variability throughout pregnancy. Median percentage of time <63 and 54 mg/dL was higher overnight than daytime ( P < 0.01). Hypoglycemic events occurred throughout the pregnancy, ranged 1–4 events per 2 weeks, significantly decreased after the 20th week, and occurred predominantly during daytime ( P < 0.01). For overnight period, hypoglycemia and events were more concentrated from 12 to 3 am. Seven prolonged hypoglycemia events without any associated SH occurred in four participants (16%), primarily overnight. Three participants experienced a single episode of SH. Conclusions: Our results suggest a higher overall risk of hypoglycemia throughout pregnancy during the overnight period with continued daytime risk of hypoglycemic events in pregnancies complicated by type 1 diabetes.
Feasibility of Closed-Loop Insulin Delivery with a Pregnancy-Specific Zone Model Predictive Control Algorithm
Özaslan, Başak , Kudva, Yogish C. , Pinsker, Jordan E. , O’Malley, Grenye , Kaur, Ravinder Jeet , Castorino, Kristin , Levister, Camilla, Trinidad, Mari Charisse, Desjardins, Donna, Church, Mei Mei , Plesser, Mitchell, McCrady-Spitzer, Shelly , Ogyaadu, Selassie, Nelson, Kristen L., Reid, Corey, Kremers, Walter K. , Rosenn, Barak, Dassau, Eyal , Kudva, Yogish C. , Doyle, Francis J , Dassau, Eyal , Kremers, Walter K , Levy, Carol J. , Nelson, Kristen, Deshpande, Sunil , Doyle, Francis J.

Mayo Clinic

Diabetes Technology & Therapeutics | March 1, 2022 | Volume: 24 | Issue: 7 | Pages: 471-480

10.1089/dia.2021.0521 | PMID 35230138 Get It

Objective: Evaluating the feasibility of closed-loop insulin delivery with a zone model predictive control (zone-MPC) algorithm designed for pregnancy complicated by type 1 diabetes (T1D). Research Design and Methods: Pregnant women with T1D from 14 to 32 weeks gestation already using continuous glucose monitor (CGM) augmented pump therapy were enrolled in a 2-day multicenter supervised outpatient study evaluating pregnancy-specific zone-MPC based closed-loop control (CLC) with the interoperable artificial pancreas system (iAPS) running on an unlocked smartphone. Meals and activities were unrestricted. The primary outcome was the CGM percentage of time between 63 and 140 mg/dL compared with participants' 1-week run-in period. Early (2-h) postprandial glucose control was also evaluated. Results: Eleven participants completed the study (age: 30.6 ± 4.1 years; gestational age: 20.7 ± 3.5 weeks; weight: 76.5 ± 15.3 kg; hemoglobin A1c: 5.6% ± 0.5% at enrollment). No serious adverse events occurred. Compared with the 1-week run-in, there was an increased percentage of time in 63–140 mg/dL during supervised CLC (CLC: 81.5%, run-in: 64%, P = 0.007) with less time >140 mg/dL (CLC: 16.5%, run-in: 30.8%, P = 0.029) and time <63 mg/dL (CLC: 2.0%, run-in:5.2%, P = 0.039). There was also less time <54 mg/dL (CLC: 0.7%, run-in:1.6%, P = 0.030) and >180 mg/dL (CLC: 4.9%, run-in: 13.1%, P = 0.032). Overnight glucose control was comparable, except for less time >250 mg/dL (CLC: 0%, run-in:3.9%, P = 0.030) and lower glucose standard deviation (CLC: 23.8 mg/dL, run-in:42.8 mg/dL, P = 0.007) during CLC. Conclusion: In this pilot study, use of the pregnancy-specific zone-MPC was feasible in pregnant women with T1D. Although the duration of our study was short and the number of participants was small, our findings add to the limited data available on the use of CLC systems during pregnancy (NCT04492566).
Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes
O’Malley, Grenye , Raghinaru, Dan, Kudva, Yogish C. , Laffel, Lori M. , Pinsker, Jordan E. , Lum, John W. , Brown, Sue A. , Anderson, Stacey M. , Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Gondor-Fredrick, Linda, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David W. , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Forlenza, Gregory P. , Slover, Robert H., Jost, Emily , Berget, Cari , Towers, Lindsey, Rossick-Solis, Alex, Ekhlaspour, Laya , Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Kollman, Craig, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Eggerman, Thomas L., Green, Neal, Reznik, Yves , Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Kudva, Yogish C. , Laffel, Lori M , Pinsker, Jordan E , Lum, John , Forlenza, Gregory P , Levy, Carol J. , Kovatchev, Boris , Oliveri, Mary Clancy , Isganaitis, Elvira , Kumari, Kanchan, Wadwa, R Paul , Alonso, G. Todd , Messer, Laurel H , Buckingham, Bruce A. , Doyle, Francis J. , Beck, Roy W. , Kollman, Craig , Renard, Eric , Cobelli, Claudio , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | January 31, 2022 | Volume: 24 | Issue: 5 | Pages: 357-361

10.1089/dia.2021.0431 | PMID 35099294 Get It

Objective: To analyze insulin delivery and glycemic metrics throughout the menstrual cycle for women with type 1 diabetes using closed loop control (CLC) insulin delivery. Methods: Menstruating women using a CLC system in a clinical trial were invited to record their menstrual cycles through a cycle-tracking application. Sixteen participants provided data for this secondary analysis over three or more complete cycles. Insulin delivery and continuous glucose monitoring (CGM) data were analyzed in relation to reported cycle phases. Results: Insulin delivery and CGM metrics remained consistent during cycle phases. Intraparticipant variability of CGM metrics and weight-based insulin delivery did not change through cycle phases. Conclusions: For this sample of menstruating women with type 1 diabetes using a CLC system, insulin delivery and glycemic metrics remained stable throughout menstrual cycle phases. Additional studies in this population are needed, particularly among women who report variable glycemic control during their cycles. Trial Registration: NCT03591354.
Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges
Kaur, Ravinder Jeet , Pinsker, Jordan E. , Gilliam, Wesley P. , McCrady-Spitzer, Shelly , Desjardins, Donna, Church, Mei Mei , Kremers, Walter K. , Dassau, Eyal , Kudva, Yogish C. , Pinsker, Jordan E , Zaniletti, Isabella, Dassau, Eyal , Kudva, Yogish C. , Kremers, Walter K , Deshpande, Sunil , Zaniletti, Isabella , Doyle, Francis J.

Mayo Clinic

Diabetes Technology & Therapeutics | January 20, 2022 | Volume: 24 | Issue: 5 | Pages: 338-349

10.1089/dia.2021.0436 | PMID 35049354 Get It

Background: Automated insulin delivery (AID) systems have not been evaluated in the context of psychological and pharmacological stress in type 1 diabetes. Our objective was to determine glycemic control and insulin use with Zone Model Predictive Control (zone-MPC) AID system enhanced for states of persistent hyperglycemia versus sensor-augmented pump (SAP) during outpatient use, including in-clinic induced stress. Materials and Methods: Randomized, crossover, 2-week trial of zone-MPC AID versus SAP in 14 adults with type 1 diabetes. In each arm, each participant was studied in-clinic with psychological stress induction (Trier Social Stress Test [TSST] and Socially Evaluated Cold Pressor Test [SECPT]), followed by pharmacological stress induction with oral hydrocortisone (total four sessions per participant). The main outcomes were 2-week continuous glucose monitor percent time in range (TIR) 70–180 mg/dL, and glucose and insulin outcomes during and overnight following stress induction. Results: During psychological stress, AID decreased glycemic variability percentage by 13.4% ( P = 0.009). During pharmacological stress, including the following overnight, there were no differences in glucose outcomes and total insulin between AID and physician-assisted SAP. However, with AID total user-requested insulin was lower by 6.9 U ( P = 0.01) for pharmacological stress. Stress induction was validated by changes in heart rate and salivary cortisol levels. During the 2-week AID use, TIR was 74.4% (vs. SAP 63.1%, P = 0.001) and overnight TIR was 78.3% (vs. SAP 63.1%, P = 0.004). There were no adverse events. Conclusions: Zone-MPC AID can reduce glycemic variability and the need for user-requested insulin during pharmacological stress and can improve overall glycemic outcomes. Clinical Trial Identifier NCT04142229.
P.140: Impact of Successful Pancreas Transplantation on Patient Reported Hypoglycemia Outcomes
Kaur, Ravinder Jeet , Rizvi, Shafaq R., Reid, Corey, Johnson, Bradley K. , McCrady-Spitzer, Shelly , Dean, Patrick G. , Kukla, Aleksandra , Kudva, Yogish C. , Rizvi, Shafaq, Smith, Byron H. , Kremers, Walter K. , Stegall, Mark D.

Mayo Clinic

Transplantation | November 28, 2021 | Volume: 105 | Issue: 12S1 | Pages: S57-S57

10.1097/01.tp.0000804624.59941.7c Get It